Prognostic value of Ki-67, CD31 and epidermal growth factor receptor expression in basal cell carcinoma

yerebakan ö., CIFTCIOGLU M. A., Akkaya B., YILMAZ E.

JOURNAL OF DERMATOLOGY, cilt.30, sa.1, ss.33-41, 2003 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 1
  • Basım Tarihi: 2003
  • Dergi Adı: JOURNAL OF DERMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.33-41
  • Anahtar Kelimeler: basal cell carcinoma, Ki-67, CD31, epidermal growth factor receptor, SUPERFICIAL BLADDER-CANCER, RECURRENCE RATES, MONOCLONAL-ANTIBODY, ANTIGEN EXPRESSION, PROLIFERATION CHARACTERISTICS, IMMUNOHISTOCHEMICAL MARKERS, MICROVESSEL DENSITY, TUMOR ANGIOGENESIS, NUCLEAR ANTIGEN, EGF RECEPTOR
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Recurrence of basal cell carcinoma following treatment is common, and the majority of recurrences appear in the first 3 years. We examined the original tumors of 26 basal cell carcinoma cases, 14 of whom had a recurrence after an average of 3.7 years, and 12 of whom had no recurrence during an average of 4.4 years follow-up. Using immunohistochemistry, we tested for Ki-67, CD31 and epidermal growth factor receptor expressions in the tumor tissue. The percentages of expression for Ki-67, CD31 and epidermal growth factor receptor were significantly higher in the recurrent tumors than in the non-recurrent ones. Expression of Ki-67 and CD31 was 271.57 +/- 17.91 and 58.1 +/- 9.37 for the recurrent group and 187.08 +/- 21.48 and 23.9 +/- 5.45 for non-recurrent group respectively (p<0.0001; p<0.0001). Expression of epidermal growth factor receptor was positive in all basal cell carcinoma cells. The staining intensity was strong in 57% of recurrent and 8.3% of non-recurrent tumors (p=0.014). These results show that Ki-67, CD31 and epidermal growth factor receptor expression differ between basal cell carcinomas which later recur and those that do not recur.